6652 Stock Overview
Eusol Biotech Co.,Ltd. focuses on research and development of new biotech drugs for sleep disorders.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Eusol Biotech Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$9.79 |
52 Week High | NT$14.95 |
52 Week Low | NT$8.56 |
Beta | -0.22 |
1 Month Change | 4.59% |
3 Month Change | 3.49% |
1 Year Change | -33.17% |
3 Year Change | -60.44% |
5 Year Change | -52.24% |
Change since IPO | -77.44% |
Recent News & Updates
Shareholder Returns
6652 | TW Biotechs | TW Market | |
---|---|---|---|
7D | 7.6% | 0.3% | 1.9% |
1Y | -33.2% | -21.1% | 26.7% |
Return vs Industry: 6652 underperformed the TW Biotechs industry which returned -21.1% over the past year.
Return vs Market: 6652 underperformed the TW Market which returned 26.7% over the past year.
Price Volatility
6652 volatility | |
---|---|
6652 Average Weekly Movement | 6.4% |
Biotechs Industry Average Movement | 4.3% |
Market Average Movement | 4.2% |
10% most volatile stocks in TW Market | 8.0% |
10% least volatile stocks in TW Market | 1.9% |
Stable Share Price: 6652 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6652's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | n/a | Hong-Jen Chang | https://www.eusol-biotech.com |
Eusol Biotech Co.,Ltd. focuses on research and development of new biotech drugs for sleep disorders. Its pipeline includes ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) for repairing neuron function; and SM-1, a 3-in-1 capsule containing 3 commercial drugs with sedative effect.
Eusol Biotech Co.,Ltd. Fundamentals Summary
6652 fundamental statistics | |
---|---|
Market cap | NT$1.34b |
Earnings (TTM) | -NT$327.00k |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-4,102x
P/E RatioIs 6652 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6652 income statement (TTM) | |
---|---|
Revenue | NT$0 |
Cost of Revenue | NT$0 |
Gross Profit | NT$0 |
Other Expenses | NT$327.00k |
Earnings | -NT$327.00k |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0024 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did 6652 perform over the long term?
See historical performance and comparison